Published in Cancer Epidemiol Biomarkers Prev on January 01, 2009
Inflammatory markers in population studies of aging. Ageing Res Rev (2010) 2.57
Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet (2013) 1.52
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood (2012) 0.96
Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem (2012) 0.94
Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol (2011) 0.81
Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci Rep (2015) 0.80
Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One (2011) 0.79
Genetic variability in IGF-1 and IGFBP-3 and body size in early life. BMC Public Health (2012) 0.78
Application of multi-SNP approaches Bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk. PLoS One (2013) 0.78
IGFBP3 polymorphisms and risk of esophageal cancer in a Chinese population. Int J Clin Exp Med (2015) 0.75
Lack of association between insulin receptor substrate2 rs1805097 polymorphism and the risk of colorectal and breast cancer: a meta-analysis. PLoS One (2014) 0.75
Polymorphisms of insulin receptor substrate 2 are putative biomarkers for pediatric medulloblastoma: considering the genetic susceptibility and pathological diagnoses. Nagoya J Med Sci (2017) 0.75
The structure of haplotype blocks in the human genome. Science (2002) 50.88
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
The effects of human population structure on large genetic association studies. Nat Genet (2004) 14.88
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Test of the National Death Index. Am J Epidemiol (1984) 8.46
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Discerning the ancestry of European Americans in genetic association studies. PLoS Genet (2007) 7.81
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest (1998) 6.76
Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol (1994) 6.47
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab (1997) 5.84
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered (2003) 4.34
Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst (1995) 3.88
Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol (2005) 3.44
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet (2007) 2.91
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab (2003) 2.40
Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol (2003) 1.98
Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev (2002) 1.92
Anthropometric characteristics and risk of multiple myeloma. Epidemiology (2005) 1.85
Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 1.77
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol (2000) 1.66
The contradictions of the insulin-like growth factor 1 receptor. Oncogene (2000) 1.52
Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet (2006) 1.42
Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst (2006) 1.41
Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun (2004) 1.37
Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.35
Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood (2003) 1.31
Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. Int J Cell Cloning (1991) 1.27
Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood (2002) 1.24
Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res (2007) 1.20
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood (2000) 1.17
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica (2005) 1.16
Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev (2006) 1.14
Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev (2007) 1.12
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Interleukin-6: historical background, genetics and biological significance. Immunol Lett (1990) 1.08
A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat (2008) 0.99
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood (2002) 0.99
Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control (2001) 0.97
Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer (2007) 0.96
Insulin-like growth factors and neoplasia. Novartis Found Symp (2004) 0.96
Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. Women. Diabetes (2007) 0.93
Insulin-like growth factor I receptor signalling in prostate cancer cells. Growth Horm IGF Res (2000) 0.81
Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. Br J Haematol (2001) 0.77
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet (2008) 16.25
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Replicating genotype-phenotype associations. Nature (2007) 16.11
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr (2006) 10.95
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst (2004) 8.77
Extended work shifts and the risk of motor vehicle crashes among interns. N Engl J Med (2005) 8.73
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Physical activity and survival after breast cancer diagnosis. JAMA (2005) 8.60
Incidental meniscal findings on knee MRI in middle-aged and elderly persons. N Engl J Med (2008) 8.40
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Genetic risk prediction--are we there yet? N Engl J Med (2009) 7.30
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr (2002) 6.96
Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet (2010) 6.60
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med (2004) 5.68
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol (2010) 4.83
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
Merging and emerging cohorts: not worth the wait. Nature (2007) 4.66
Multiple myeloma. Lancet (2009) 4.60
A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet (2008) 4.57
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43